Angela Sardaro1, Barbara Turi2, Lilia Bardoscia3, Cristina Ferrari4, Giuseppe Rubini4, Angela Calabrese5, Federica Ammirati1, Antonietta Grillo2, Annamaria Leo2, Filomenamila Lorusso6, Antonio Santorsola2, Antonio Amato Stabile Ianora1, Arnaldo Scardapane1. 1. Interdisciplinary Department of Medicine, Section of Radiology and Radiation Oncology, University of Bari "Aldo Moro", Bari, Italy. 2. Radiation Oncology Unit, Azienda Ospedaliero-Universitaria Policlinico, Bari, Italy. 3. Radiation Therapy Unit, Department of Oncology and Advanced Technology, Azienda USL-IRCCS di Reggio Emilia, Reggio Emilia, Italy. 4. Nuclear Medicine Unit, Interdisciplinary Department of Medicine, University of Bari Aldo Moro, Bari, Italy. 5. Department of Radiology, IRCCS Istituto Tumori "Giovanni Paolo II", Bari, Italy. 6. Department of Radiology, "Di Venere" Hospital of Bari, Bari, Italy.
Abstract
BACKGROUND AND PURPOSE: Volumetric modulated arc radiotherapy (RT) has become pivotal in the treatment of prostate cancer recurrence (RPC) to optimize dose distribution and minimize toxicity, thanks to the high-precision delineation of prostate bed contours and organs at risk (OARs) under multiparametric magnetic resonance (mpMRI) guidance. We aimed to assess the role of pre-treatment mpMRI in ensuring target volume coverage and normal tissue sparing. MATERIAL AND METHODS: Patients with post-prostatectomy RPC eligible for salvage RT were prospectively recruited to this pilot study. Image registration between planning CT scan and T2w pre-treatment mpMRI was performed. Two sets of volumes were outlined, and DWI images/ADC maps were used to facilitate precise gross tumor volume (GTV) delineation on morphological MRI scans. Two rival plans (mpMRI-based or not) were drawn up. RESULTS: Ten patients with evidence of RPC after prostatectomy were eligible. Preliminary data showed lower mpMRI-based clinical target volumes than CT-based RT planning (p = 0.0003): median volume difference 17.5 cm3. There were no differences in the boost volume coverage nor the dose delivered to the femoral heads and penile bulb, but median rectal and bladder V70Gy was 4% less (p = 0.005 and p = 0.210, respectively) for mpMRI-based segmentation. CONCLUSIONS: mpMRI provides high-precision target delineation and improves the accuracy of RT planning for post-prostatectomy RPC, ensures better volume coverage with better OARs sparing and allows non-homogeneous dose distribution, with an aggressive dose escalation to the GTV. Randomized phase III trials and wider datasets are needed to fully assess the role of mpMRI in optimizing therapeutic strategies.
BACKGROUND AND PURPOSE: Volumetric modulated arc radiotherapy (RT) has become pivotal in the treatment of prostate cancer recurrence (RPC) to optimize dose distribution and minimize toxicity, thanks to the high-precision delineation of prostate bed contours and organs at risk (OARs) under multiparametric magnetic resonance (mpMRI) guidance. We aimed to assess the role of pre-treatment mpMRI in ensuring target volume coverage and normal tissue sparing. MATERIAL AND METHODS: Patients with post-prostatectomy RPC eligible for salvage RT were prospectively recruited to this pilot study. Image registration between planning CT scan and T2w pre-treatment mpMRI was performed. Two sets of volumes were outlined, and DWI images/ADC maps were used to facilitate precise gross tumor volume (GTV) delineation on morphological MRI scans. Two rival plans (mpMRI-based or not) were drawn up. RESULTS: Ten patients with evidence of RPC after prostatectomy were eligible. Preliminary data showed lower mpMRI-based clinical target volumes than CT-based RT planning (p = 0.0003): median volume difference 17.5 cm3. There were no differences in the boost volume coverage nor the dose delivered to the femoral heads and penile bulb, but median rectal and bladder V70Gy was 4% less (p = 0.005 and p = 0.210, respectively) for mpMRI-based segmentation. CONCLUSIONS: mpMRI provides high-precision target delineation and improves the accuracy of RT planning for post-prostatectomy RPC, ensures better volume coverage with better OARs sparing and allows non-homogeneous dose distribution, with an aggressive dose escalation to the GTV. Randomized phase III trials and wider datasets are needed to fully assess the role of mpMRI in optimizing therapeutic strategies.
Authors: Melina Arnold; Henrike E Karim-Kos; Jan Willem Coebergh; Graham Byrnes; Ahti Antilla; Jacques Ferlay; Andrew G Renehan; David Forman; Isabelle Soerjomataram Journal: Eur J Cancer Date: 2013-10-08 Impact factor: 9.162
Authors: Piet Dirix; Lien van Walle; Filip Deckers; François Van Mieghem; Guido Buelens; Paul Meijnders; Philippe Huget; Steven Van Laere Journal: Acta Oncol Date: 2016-09-01 Impact factor: 4.089
Authors: Thomas M Pisansky; Ian M Thompson; Richard K Valicenti; Anthony V D'Amico; Shalini Selvarajah Journal: J Urol Date: 2019-08-08 Impact factor: 7.450
Authors: Felipe Couñago; Gemma Sancho; Violeta Catalá; Diana Hernández; Manuel Recio; Sara Montemuiño; Jhonathan Alejandro Hernández; Antonio Maldonado; Elia Del Cerro Journal: World J Clin Oncol Date: 2017-08-10
Authors: Constantinos Zamboglou; Matthias Eiber; Thomas R Fassbender; Matthias Eder; Simon Kirste; Michael Bock; Oliver Schilling; Kathrin Reichel; Uulke A van der Heide; Anca L Grosu Journal: Phys Imaging Radiat Oncol Date: 2018-11-05
Authors: Daniel Wegener; Alexandra Thome; Frank Paulsen; Cihan Gani; Jessica Boldt; Sarah Butzer; Daniela Thorwarth; David Moennich; Marcel Nachbar; Arndt-Christian Müller; Daniel Zips; Simon Boeke Journal: J Clin Med Date: 2022-08-09 Impact factor: 4.964